OncoTherapy Science, Inc.
Research OncoTherapy Science, Inc. (4564.T) on Bullrun: market cap JPY 7.35B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4564.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 7.35B
- Financial periodFY2026
- RevenueJPY 808.53M
- Revenue growth7.8%
- Net income-JPY 910.64M
- Free cash flow-JPY 984.97M
- Gross margin1.7%
Valuation Snapshot
latest market cap is JPY 7.35B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 808.53M | -JPY 910.64M | -JPY 984.97M | 1.7% | -2.77 | JPY 2.09B | n/a | JPY 2.14B |
| FY2025 | JPY 750.05M | -JPY 815.29M | -JPY 815.30M | -1.7% | -3.12 | JPY 833.88M | n/a | JPY 729.11M |
| FY2024 | JPY 610.12M | -JPY 1.29B | -JPY 1.23B | -29.1% | -6.05 | JPY 527.66M | n/a | JPY 353.67M |
| FY2023 | JPY 1.13B | -JPY 1.12B | -JPY 800.29M | 3.7% | -5.81 | JPY 1.12B | n/a | JPY 855.17M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 7.35B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About OncoTherapy Science, Inc.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OncoTherapy Science, Inc.'s market cap?
OncoTherapy Science, Inc.'s market capitalization is JPY 7.35B.
What does OncoTherapy Science, Inc. do?
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage.